Chargement en cours...
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
PURPOSE: EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. METHODS: This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth fact...
Enregistré dans:
| Auteurs principaux: | , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Clinical Oncology
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3589701/ https://ncbi.nlm.nih.gov/pubmed/23401451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.43.3912 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|